Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Article in English | IMSEAR | ID: sea-42291

ABSTRACT

Fifty obese patients with a body mass index greater than 25 kg/m2 were randomized into 3 groups: control (C = 19), placebo (P = 18) and dexfenfluramine (D = 18). A behavioral modification program which included eating habits, exercise, attitudes, social relationships and six steps to lifetime weight control was taught every week. All patients strictly followed the food manual and recorded their behavior, physical activity and food intake every day through 12 weeks. Placebo and dexfenfluramine 30 mg/day were given in a double blind placebo controlled study. The results showed that all 3 groups had significant decreases in rest times and increased activity times (p < 0.05) and significant reductions of the average total daily energy, carbohydrate and fat intake (p < 0.05). They all lost weight. Mean +/- SEM cumulative weight loss was 8.3 +/- 0.7 kg in group D, 3.3 +/- 1 kg, in group P and 2.9 +/- 0.7 kg, in group C. The mean additional weight loss of 5 kg, and 5.4 kg seen with dexfenfluramine being highly significant (p < 0.001) from group P and C most likely due to increased thermogenesis. Significant (p < 0.05) and gradual reduction of biceps, triceps skinfold and per cent body fat were constantly observed only in the dexfenfluramine group. There were no significant differences among the 3 groups regarding blood pressure, heart rate, hematologic, lipids and biochemical profiles.


Subject(s)
Adolescent , Adult , Aged , Anthropometry , Appetite Depressants/therapeutic use , Behavior Therapy , Body Composition , Dexfenfluramine/therapeutic use , Double-Blind Method , Eating , Female , Humans , Male , Middle Aged , Obesity/drug therapy
2.
Article in Spanish | LILACS | ID: lil-274524

ABSTRACT

Presentamos la transcripción de un Coloquio efectuado acerca del lugar que ocupan la psicoterapia y farmacoterapia en el tratamiento de los trastornos de personalidad. El coloquio muestra los diferentes argumentos, empíricos, clínicos y teóricos, que fundamentan la indicación de uno u otro método en cada caso particular. Desde el punto de vista de la farmacoterapia, que presentan las evidencias que apoyan un sustrato neurobiológico para los trastornos de personalidad. Especial énfasis es otorgado a las relaciones que existirían entre sistemas de neurotransmisión, dimensiones de personalidad, presentación clínica y respuesta a farmacoterapia. Asimismo, son examinados los problemas teóricos que supone clasificar los trastornos de personalidad en base a criterios puramente categoriales. Desde el punto de vista de la psicoterapia se examinan diversos aspectos de ella en relación a los trastornos de personalidad: su indicación, su relación e integración con otras formas de tratamiento (p.ej. farmacoterapia); su implementación en el ámbito institucional y las formas de cooperación multi e interdisciplinaria. Se examina asimismo la función de la psicoterapia como un marco de referencia que otorga sentido, no sólo a los conflictos del paciente, sino al conjunto de intervenciones efectuadas. Finalmente, se examina el problema del monismo vs dualismo metódico y sus implicancias para la praxis futura


Subject(s)
Humans , Personality Disorders/drug therapy , Psychotherapy , Personality Disorders/therapy , Placebo Effect , Fluoxetine/therapeutic use , Dexfenfluramine/therapeutic use , Patient Care Team , Psychotherapeutic Processes
SELECTION OF CITATIONS
SEARCH DETAIL